低剂量紫杉醇联合顺铂治疗老年晚期非小细胞肺癌的有效性及安全性  

Efficacy and safety of low-dose paclitaxel combined with cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer

作　　者：潘元腾 李扬 庄佳芳 欧阳山丹 PAN Yuanteng;LI Yang;ZHUANG Jiafang;OUYANG Shandan(Department of Pharmacy,the 73rd Group Military Hospital of the Chinese People′s Liberation Army,Fujian Province,Xiamen 361001,China)

机构地区：[1]中国人民解放军陆军第七十三集团军医院药剂科,福建省厦门市361001

出　　处：《临床合理用药》2025年第7期14-17,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：厦门市医疗卫生指导性项目(3502Z20214ZD1272)。

摘　　要：目的观察低剂量紫杉醇联合顺铂治疗老年晚期非小细胞肺癌的有效性及安全性。方法以随机数字表法将2022年9月—2024年9月中国人民解放军陆军第七十三集团军医院收治的80例老年晚期非小细胞肺癌患者分为低剂量组和常规剂量组,各40例。常规剂量组采用常规剂量紫杉醇联合顺铂化疗,低剂量组予低剂量紫杉醇联合顺铂化疗,2组治疗周期均为6周。比较2组近期疗效,治疗前后免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、生活质量评分及不良反应。结果低剂量组与常规剂量组疾病控制率比较无统计学差异(70.00%vs.72.50%,P=1.000)。治疗6周后,2组CD4^(+)、CD4^(+)/CD8^(+)升高,CD8^(+)降低,且低剂量组相较常规剂量组变化幅度更大(P<0.01);低剂量组躯体、社会功能与2组认知、角色、情绪功能评分升高,且低剂量组相较常规剂量组更高(P<0.05或P<0.01),常规剂量组躯体、社会功能评分与治疗前比较无统计学差异(P>0.05);低剂量组不良反应总发生率为32.50%,低于常规剂量组的55.00%(χ^(2)=4.114,P=0.043)。结论对于老年晚期非小细胞肺癌患者,使用低剂量紫杉醇联合顺铂化疗方案治疗,同常规剂量相比疗效无显著差异,但对患者免疫功能影响更小,生活质量更好,不良反应更少,安全性更高。Objective To observe the efficacy and safety of low-dose paclitaxel combined with cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer.Methods A total of 80 elderly patients with advanced non-small cell lung cancer admitted to the 73rd Group Military Hospital of the Chinese People′s Liberation Army from September 2022 to September 2024 were randomly divided into low-dose group and conventional dose group,with 40 cases in each group.The conventional dose group was treated with conventional dose paclitaxel combined with cisplatin chemotherapy,and the low-dose group was treated with low-dose paclitaxel combined with cisplatin chemotherapy.The treatment cycles of both groups were 6 weeks.The short-term efficacy,immune function indexes(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),quality of life score before and after treatment,and adverse reactions were compared between the two groups.Results There was no significant difference in disease control rate between low-dose group and conventional dose group(70.00%vs.72.50%,P=1.000).After 6 weeks of treatment,CD4^(+),CD4^(+)/CD8^(+)increased and CD8^(+)decreased in both groups,and the change amplitude of low-dose group was greater than that of conventional dose group(P<0.01).The scores of physical and social functions in the low-dose group and cognitive,role and emotional functions in the two groups were increased,and the scores in the low-dose group were higher than those in the conventional dose group(P<0.05 or P<0.01).The scores of physical and social functions in the conventional dose group were not significantly different from those before treatment(P>0.05).The total incidence of adverse reactions in the low-dose group was 32.50%,which was lower than 55.00%in the conventional dose group(χ^(2)=4.114,P=0.043).Conclusion For elderly patients with advanced non-small cell lung cancer,the use of low-dose paclitaxel combined with cisplatin chemotherapy has no significant difference in efficacy compared with conventional dose,but it has less impact on

关 键 词：非小细胞肺癌 晚期 紫杉醇 低剂量 顺铂 近期疗效 安全性 

分 类 号：R73[医药卫生—肿瘤]